Send a text

In January 2026, the FDA sharpened the line between helpful software and regulated medical devices. If your AI sits inside an EHR, providing "black box" recommendations that a clinician can’t independently verify in seconds, you aren't just drifting into a regulatory gray area, you’re likely standing outside the "safe zone."

In this episode, we break down the high-stakes intersection of FDA transparency, OIG inducement analysis, and the reality of clinical workflows.

In this episode, we cover:

• The 2026 FDA Update: Why "independence" is the new metric for non-device CDS.
• The Transparency Test: If a physician has to call your engineering team to explain a recommendation, you've already lost.
• OIG & The Anti-Kickback Statute: How "nudging" prescribing behavior creates massive financial liability, regardless of what you call your software.
• Automation Bias: How "fast and confident" AI leads to clinician reliance that regulators now view as a red flag.
• The FTC Factor: Why vague disclosures and hidden logic are no longer defensible under consumer protection standards.

Key Takeaway:

Regulators don't care if the tech works; they care if the compliance story holds up. If you cannot prove your recommendations are separated from commercial influence and fully explainable, you are exposed.

Are you ready to defend your AI? Don't wait for an investigator to walk through your door.

Subscribe to the KLF Deep Dive Podcast & Newsletter to navigate these risks before they turn into enforcement problems.

Support the show

www.kulkarnilawfirm.com